Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
SCRI Development Innovations, LLC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07637578CT.gov A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07382739CT.gov A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" | — | Recruiting | — | — | — |
NCT07280013CT.gov A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | — | Recruiting | — | — | — |
NCT07348393CT.gov A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Not Yet Recruiting | — | — | — |
NCT07032714CT.gov Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06988488CT.gov A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06997081CT.gov ERd Combination Treatment in Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06832865CT.gov ELISA in Relapsed/Refractory MM | — | Recruiting | — | — | — |
NCT07105059CT.gov A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06974786CT.gov Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | — | Recruiting | — | — | — |
Show 41 more trialsShow fewer
NCT06918002CT.gov Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | — | Recruiting | — | — | — |
NCT06581848CT.gov Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | — | Active Not Recruiting | — | — | — |
NCT06947083CT.gov Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | — | Recruiting | — | — | — |
NCT06931704CT.gov Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | — | Not Yet Recruiting | — | — | — |
NCT06627751CT.gov Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | — | Recruiting | — | — | — |
NCT06799026CT.gov A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06015542CT.gov Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | — | Recruiting | — | — | — |
NCT06855121CT.gov The Norwegian Immunotherapy in Multiple Myeloma Study | — | Recruiting | — | — | — |
NCT06711705CT.gov Elranatamab in Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06645678CT.gov Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06592222CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies | — | Completed | — | — | — |
NCT06207799CT.gov Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT06048250CT.gov Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06138275CT.gov Elranatamab in R/R Multiple Myeloma | — | Recruiting | — | — | — |
NCT06163898CT.gov A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT06121843CT.gov A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06215118CT.gov A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | — | Recruiting | — | — | — |
NCT06152575CT.gov MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | — | Recruiting | — | — | — |
NCT05981209CT.gov Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | — | Active Not Recruiting | — | — | — |
NCT06106945CT.gov AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06057402CT.gov Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | — | Recruiting | — | — | — |
NCT06050512CT.gov Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT06504524CT.gov A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US | — | Completed | — | — | — |
NCT05927571CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | — | Recruiting | — | — | — |
NCT05932290CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05651932CT.gov A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05552976CT.gov A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | — | Active Not Recruiting | — | — | — |
NCT05675449CT.gov A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT05372354CT.gov A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05565391CT.gov A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05519085CT.gov A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT05317416CT.gov Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | — | Active Not Recruiting | — | — | — |
NCT05228470CT.gov A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT05014412CT.gov A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment | — | Completed | — | — | — |
NCT05020236CT.gov A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | — | Recruiting | — | — | — |
NCT03989414CT.gov A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03374085CT.gov A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Terminated | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT05238311CT.gov Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mezigdomide (this asset) | SCRI Development Innovations, LLC | Approved | BB · 66 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Mezigdomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Leukemia | — | P1/2 | CC · 43 |
| Mixed Phenotype Acute Leukemia | — | P1/2 | CC · 43 |
| Acute Myeloid Leukemia With Mutated NPM1 | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mezigdomide in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mezigdomide-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →